<DOC>
	<DOCNO>NCT00002495</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without doxorubicin vinblastine treat patient stage I stage II Hodgkin 's disease .</brief_summary>
	<brief_title>SWOG-9133 RT w/ w/o Doxorubicin Vinblastine Stage I Stage II Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Compare progression-free overall survival patient clinical Stage IA/IIA Hodgkin 's disease undergone laparotomy randomize treatment subtotal nodal irradiation vs. without 3 course doxorubicin/vinblastine . II . Compare long-term toxicity associate treatment , include cardiopulmonary toxicity , secondary malignancy , infertility . III . Identify subgroups patient ( base age , gender , tumor histology , number disease site , presence high neck presentation ) particularly responsive treatment . OUTLINE : Randomized study . Arm I : Radiotherapy . Subtotal nodal irradiation use megavoltage equipment ( 4-10 MeV ) . Arm II : 2-Drug Combination Chemotherapy follow Radiotherapy . Doxorubicin , DOX , NSC-123127 ; Vinblastine , VBL , NSC-49842 ; follow subtotal nodal irradiation Arm I . PROJECTED ACCRUAL : 210 patients/arm enrol 7 year .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven Hodgkin 's disease , subclassified accord Rye system Clinical Stages IA , IEA , IIA , IIEA accord modify Ann Arbor system Staging laparotomy allow Completely resected disease allow Residual disease , present , must bidimensionally measurable No mediastinal mass great 1/3 maximum chest diameter No infradiaphragmatic presentation No pericardial E lesion ( small pericardial effusion absence nodular pericardial disease allow ) Concurrent registration protocol SWOG9208 ( qualityoflife study ) require unless patient understand read English PATIENT CHARACTERISTICS : Age : 16 Performance status : SWOG 02 Hematopoietic : AGC least 2,000 Platelets within normal limit Hepatic : Bilirubin within normal limit Renal : Creatinine within normal limit Cardiovascular : LVEF normal No serious EKG abnormality Pulmonary : No serious pulmonary condition Other : No serious medical condition Hodgkin 's disease No known AIDS HIVassociated complex No second malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer Adequately treat situ carcinoma cervix No pregnant lactate woman Adequate contraception require fertile patient Blood/body fluid analyse determine eligibility complete within 14 day prior registration ; image study tumor measurement complete within 28 day prior registration ; screen exam blood/body fluid analysis , image study nonmeasurable disease uninvolved organ complete within 42 day prior registration PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy reason Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy reason Surgery : No stag laparotomy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
</DOC>